Sigma Healthcare Limited

DB:S5YA Stock Report

Market Cap: €2.6b

Sigma Healthcare Valuation

Is S5YA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of S5YA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: S5YA (€1.69) is trading below our estimate of fair value (€9.91)

Significantly Below Fair Value: S5YA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for S5YA?

Key metric: As S5YA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for S5YA. This is calculated by dividing S5YA's market cap by their current revenue.
What is S5YA's PS Ratio?
PS Ratio1.2x
SalesAU$3.48b
Market CapAU$4.21b

Price to Sales Ratio vs Peers

How does S5YA's PS Ratio compare to its peers?

The above table shows the PS ratio for S5YA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.5x
ILM1 Medios
0.2x6.1%€328.6m
HAEK HAEMATO
0.2xn/a€66.9m
SYAB SYNLAB
1x4.4%€2.5b
RHK RHÖN-KLINIKUM
0.4x2.1%€823.3m
S5YA Sigma Healthcare
1.2x21.5%€4.2b

Price-To-Sales vs Peers: S5YA is expensive based on its Price-To-Sales Ratio (1.2x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does S5YA's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
EIF MedNation
0.1xn/aUS$4.74m
TLIK Arzneiwerk VIDA
0.07xn/aUS$4.64m
No more companies available in this PS range
S5YA 1.2xIndustry Avg. 0.6xNo. of Companies3PS00.40.81.21.62+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: S5YA is expensive based on its Price-To-Sales Ratio (1.2x) compared to the European Healthcare industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is S5YA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

S5YA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: S5YA is expensive based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst S5YA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.69
€1.15
-31.7%
25.3%€1.55€0.62n/a7
Nov ’25€1.15
€0.77
-33.2%
20.5%€0.99€0.48n/a7
Oct ’25€1.08
€0.77
-28.9%
20.5%€0.99€0.48n/a7
Sep ’25€0.74
€0.68
-8.3%
18.4%€0.84€0.47n/a8
Aug ’25€0.74
€0.68
-8.3%
18.4%€0.84€0.47n/a8
Jul ’25€0.74
€0.68
-9.2%
16.3%€0.80€0.48n/a8
Jun ’25€0.73
€0.68
-8.0%
16.3%€0.80€0.48n/a8
May ’25€0.74
€0.68
-9.2%
16.9%€0.79€0.47n/a8
Apr ’25€0.76
€0.68
-10.4%
16.9%€0.79€0.47n/a8
Mar ’25€0.66
€0.54
-18.1%
10.0%€0.64€0.47n/a8
Feb ’25€0.60
€0.54
-10.6%
10.0%€0.64€0.47n/a8
Jan ’25€0.61
€0.51
-16.5%
6.6%€0.55€0.45n/a8
Dec ’24€0.42
€0.50
+20.0%
5.0%€0.54€0.45n/a8
Nov ’24€0.38
€0.50
+31.9%
5.4%€0.54€0.45€1.157
Oct ’24€0.41
€0.50
+20.4%
5.4%€0.54€0.45€1.087
Sep ’24€0.46
€0.50
+9.6%
4.2%€0.55€0.49€0.747
Aug ’24€0.46
€0.50
+9.6%
4.2%€0.55€0.49€0.747
Jul ’24€0.49
€0.50
+1.3%
11.7%€0.56€0.36€0.748
Jun ’24€0.38
€0.35
-7.2%
15.1%€0.39€0.23€0.738
May ’24€0.41
€0.35
-14.0%
15.9%€0.39€0.23€0.747
Apr ’24€0.42
€0.36
-14.1%
12.7%€0.40€0.26€0.768
Mar ’24€0.41
€0.38
-5.6%
14.3%€0.46€0.28€0.668
Feb ’24€0.40
€0.38
-3.8%
14.3%€0.46€0.28€0.608
Jan ’24€0.36
€0.38
+8.1%
14.3%€0.46€0.28€0.618
Dec ’23€0.39
€0.38
-1.3%
14.3%€0.46€0.28€0.428
Nov ’23€0.40
€0.38
-4.7%
14.3%€0.46€0.28€0.388

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Sensus Healthcare

US$143.9m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$8.25

7D

4.4%

1Y

263.8%

Shandong Weigao Group Medical Polymer

HK$20.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.9%

1Y

-37.7%

LNA Santé

€240.3m

Engages in the management and operation of health establishments.

2N3

€23.00

7D

1.5%

1Y

17.7%